Previous Close | 2.6000 |
Open | 2.6500 |
Bid | 2.6400 x 200 |
Ask | 2.6800 x 200 |
Day's Range | 2.5000 - 2.7300 |
52 Week Range | 2.3300 - 42.0000 |
Volume | |
Avg. Volume | 1,247,181 |
Market Cap | 5.079M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -286.4000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
London, United Kingdom--(Newsfile Corp. - May 21, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, reported that it expects to implement a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will continue on The Nasdaq Capital Market under the symbol "AKAN". The ...
London, United Kingdom--(Newsfile Corp. - May 20, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has closed its previously announced second registered direct offering for the sale and issuance of 2,491,381common shares at a purchase price of $0.1031 and 12,057,600 pre-funded warrants to purchase 12,057,600 common shares at $0.103 per share, priced at the Minimum Price under the Nasdaq rules. The pre-funded warra
London, United Kingdom--(Newsfile Corp. - May 17, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical cannabis company, today announced that it has entered into a second securities purchase agreement with an accredited investor whereby the investor has agreed to purchase 2,491,381common shares at a purchase price of $0.1031 and 12,057,600 pre-funded warrants to purchase 12,057,600 common shares at $0.103 per share in a registered direct offering priced at Mi